Maravai LifeSciences Holdings Inc. (MRVI) shares reached a 52-week high of $8.15 on Tuesday, closing at $8.12 with a market capitalization of $1.87 billion.
The biotech company’s stock has gained 193.5% over the past 12 months, including a 24.91% advance over the past week. The rally follows second-quarter results that exceeded revenue and earnings expectations. Revenue rose 9% year-over-year to $51.4 million, surpassing the $48.68 million forecast. Adjusted loss per share narrowed to -$0.02, beating Wall Street’s estimate of -$0.04.
Despite the strong performance, Maravai maintained a cautious outlook, contributing to a subsequent pullback in trading. Analysts cited by InvestingPro data do not expect the company to achieve profitability this year, and the stock is currently assessed as overvalued relative to its fair value estimate.
InvestingPro’s platform flagged the 52-week high as one of 13 key data points, underscoring the stock’s recent momentum amid broader market volatility in biotech equities.
